News Breaks |
|
|
| March 1, 2013 |
| 14:52 EDT |  | BIIB, SHPG, BMY | Biogen, Shire among targets considered by Bristol-Myers, WSJ says
Bristol-Myers Squibb (BMY) has recently studied a possible acquisition of Biogen Idec (BIIB) and previously engaged advisers to look into the acquisition of Shire (SHPG), according to The Wall Street Journal, citing people familiar with the matters. Shares of both smaller companies rose following the initial report. In afternoon trading, Biogen advanced 0.7% to $167.50, while Shire rose 1.7% to $95.28. Reference Link |
|
|
News For BIIB;SHPG;BMY From The Last 14 Days Check below for free stories on BIIB;SHPG;BMY the last two weeks. |
|
|
| May 20, 2013 |
| 15:57 EDT |  | BIIB | Biogen IMS numbers should not be adjusted down at ISI Group
ISI Group confirmed with Biogen that Tecfidera is not captured by IMS and numbers should not be adjusted downward to reflect free drugs dispensed. |
|
| 10:03 EDT |  | SHPG, BMY | Shire advances after report renews takeover speculation
 Subscribe for More Information |
|
| 07:39 EDT | | BIIB | Biogen weekly MS drug scripts up 26.5%, says Citigroup
Citigroup says weekly scripts for Biogen's multiple sclerosis drug Tecfidera were up 26.5% to 1,621. Citi says the launch of Tecfidera is on track to beat Q2 estimates by a wide margin and it keeps a Buy rating on shares of Biogen. |
|
| 07:27 EDT |  | SHPG | American Psychiatric Association to host annual meeting
Subscribe for More Information |
|
| 07:01 EDT | | SHPG | Sangamo BioSciences announces positive data for Vivo Protein platform
Sangamo BioSciences (SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire (SHPG) to develop ZFP Therapeutics for both hemophilia A and B using this approach. |
|
| 06:30 EDT | | SHPG, BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT | | BMY, SHPG | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT |  | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
| |
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 08:55 EDT | | BMY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT | | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 07:29 EDT | | BIIB | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
|
| May 15, 2013 |
| 11:28 EDT | | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
|
| 09:43 EDT | | BMY | Active equity option families trading on open
Subscribe for More Information |
|
| May 14, 2013 |
| 15:09 EDT | | BIIB | Biogen has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. |
|
| 07:24 EDT | | BMY, SHPG | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 13, 2013 |
| 11:12 EDT | | BIIB | Biogen MS drug scripts grew 38% week-over-week, says Leerink
Subscribe for More Information |
| |
|
|
|
|
